New Market Launch: TIEFENBACHER PHARMACEUTICALS successfully launces generic version of the prostate cancer medicines Abiraterone and the value-added product Abiraterone/Prednisolone
We at Tiefenbacher Pharmaceuticals aim to improve peoples´ lives around the world by making medicines better affordable, better available, and better than before! That´s why we are excited to share that we have successfully prepared the launch of the generic versions of Abiraterone and the value-added product Abiraterone/Prednisolone for a market entry in Europe (EU) – authorized by the European Medicines Agency (EMA). That means that Abiraterone contains the same active substance and works in the same way as a ‘referenc medicine’ already approved in the EU called Zytiga.
For the mono product Abiraterone, we were able to achieve a day one launch after patent expiration, making this important therapy finally more affordable for patients around the world. With the combination product Abiraterone/Prednisolone, we offer a value-added product which comes in a special combi blister packaging improving patients´ compliance, enhancing physicians´ convenience, and protecting the environment.
Abiraterone and the combination product Abiraterone/Prednisolone are used to treat men with prostate cancer. The 500 mg (mono product) and 500 mg + 5 mg (combination product) tablets will be marketed in Europe by our partners. A launch of generics in further international markets will follow soon. The lower cost of generic drugs promotes patient affordability and contributes to lower per capita healthcare spending. Tiefenbacher Pharmaceuticals is committed to continuously making high-quality medicines better affordable, better global availability, and better than before.
We will keep you updated about launches of this and other products in further international markets.
TIEFENBACHER PHARMACEUTICALS, a part of Tiefenbacher Group, develops and commercializes generic, value added, and innovative pharmaceuticals as well as medical devices worldwide. We provide over 180+ pharmaceutical products across various therapeutic categories in 10+ dosage forms. With our in-house product development and manufacturing, we can address specific therapeutic needs in unique formulations of prescription drugs (Rx) and over-the-counter (OTC) medicines for global markets (including highly potent drugs).
For more information about our finished dosage forms and healthcare solutions, please contact Tiefenbacher Pharmaceuticals: info@tiefenbacher.com or please visit us on: www.tiefenbacher-pharmaceuticals.com
About Tiefenbacher Group – Pioneering Healthcare since 1963
Tiefenbacher Group is a purpose-driven and 100% family-owned healthcare company providing best-in-class solutions along the entire pharmaceutical value chain. From the initial idea to market access of high-quality medicines around the world: We distribute APIs and develop, produce, and register finished dosage forms (FDFs) including highly potent drugs as well as medical devices. Our purpose is to improve people’s lives by making pharmaceuticals more affordable, more available, and better than ever before.
For further information about TIEFENBACHER GROUP and our solutions for better healthcare and our in-house capabilities to develop and commercialize pharmaceutical products for global markets (including highly potent drugs) please contact us by email at info@tiefenbacher.com or visit us on: www.tiefenbachergroup.com
